{
  "source": "PA-Med-Nec-Relistor.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2076-12\nProgram Prior Authorization/Medical Necessity\nMedication Relistor® (methylnaltrexone bromide)\nP&T Approval Date 2/2016, 12/2016, 11/2017, 7/2018, 7/2019, 7/2020, 7/2021, 7/2022,\n7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nAmitiza®- (lubiprostone)*, Relistor (methylnaltrexone bromide) and Symporic® (naldemedine) are\nopioid antagonists indicated for the treatment of opioid-induced constipation (OIC) in adult\npatients with chronic non-cancer pain including patients with chronic pain related to prior cancer\nor its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. Relistor\ninjection is also indicated for the treatment of opioid-induced constipation in patients with\nadvanced illness or pain caused by active cancer who require opioid dosage escalation for\npalliative care. Physicians and patients should periodically assess the need for continued\ntreatment with Relistor.\nThis prior authorization program is intended to encourage the use of lower cost alternatives. This\nprogram requires a member to try lower-cost options before providing coverage for Relistor.\n2. Coverage Criteriaa:\nA. Relistor Injection\n1. Initial Authorization\na. Relistor injection will be approved based on documentation (e.g. chart notes)\ndemonstrating one of the following:\n1) Diagnosis of opioid induced constipation in patients with advanced illness\nreceiving palliative care\n-OR-\n2) Both of the following\na) ONE of the following\ni. Diagnosis of opioid induced constipation with chronic, non-cancer pain\n-OR-\nii. Diagnosis of opioid induced constipation in patients with chronic pain\nrelated to prior cancer diagnosis or cancer treatment who do not require\nfrequent (e.g., weekly) opioid dosage escalation\n-AND-\n© 2024 UnitedHealthcare Services Inc.\n1\nb) One of the following:\ni. The patient is not able to swallow oral medications.\n-OR-\nii. History of failure, contraindication or intolerance to",
    "scalation\n-AND-\n© 2024 UnitedHealthcare Services Inc.\n1\nb) One of the following:\ni. The patient is not able to swallow oral medications.\n-OR-\nii. History of failure, contraindication or intolerance to BOTH of the\nfollowing:\n• lubiprostone (generic Amitiza)\n-AND-\n• Symproic\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Relistor injection will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Relistor injection therapy\nAuthorization will be issued for 12 months.\nB. Relistor Tablets*\n1. Initial Authorization\na. Relistor tablets will be approved based on BOTH of the following:\n1) ONE of the following\ni. Diagnosis of opioid induced constipation with chronic, non-cancer pain\n-OR-\nii. Diagnosis of opioid induced constipation in patients with chronic pain\nrelated to prior cancer diagnosis or cancer treatment who do not require\nfrequent (e.g., weekly) opioid dosage escalation\n-AND-\n2) History of failure, contraindication or intolerance to BOTH of the\nfollowing:\na) lubiprostone (generic Amitiza)\n-AND-\n© 2024 UnitedHealthcare Services Inc.\n2\nb) Symproic\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Relistor tablets will be approved based on the following criterion:\n1) Documentation of positive clinical response to Relistor tablet therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Brand Amitiza and Relistor tablets are typically excluded from coverage\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in p",
    "vious claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n• Notification/Prior Authorization may be in place.\n4. References:\n1. Amitiza [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; November\n2020.\n2. Relistor [package insert]. Bridgewater, NJ: Bausch Health US, LLC.; May 2024.\n3. Symproic [package insert]. Raleigh, NC: BioDelivery Sciences International. July 2021.\n4. Chang, L, Sultan, S, et. al. AGA Clinical Practice Guideline on the Pharmacological Management\nof Irritable Bowel Syndrome with Constipation. Gastroenterology: 2022; 162:118-36.\nProgram Prior Authorization/Medical Necessity – Relistor\nChange Control\nDate Change\n2/2016 New program\n7/2016 Added Indiana and West Virginia coverage information.\n11/2016 Added California coverage information.\n12/2016 Added coverage information for Relistor Tablets\n11/2017 Annual review. Updated background section and criteria with enhanced\nindication for opioid inducted constipation. Updated references.\n7/2018 Removed Movantik as a first line option and added Symproic. Updated\nreferences.\n7/2019 Annual review. Updated background section and references.\n7/2020 Annual review. Updated initial authorization and references.\n7/2021 Annual review. Updated references.\n© 2024 UnitedHealthcare Services Inc.\n3\n7/2022 Annual review. Updated references.\n7/2023 Annual review. Removed OTC laxative and added generic Amitiza as\nstep for Relistor. Updated references.\n7/2024 Annual review. Updated references.\n© 2024 UnitedHealthcare Services Inc.\n4"
  ]
}